3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Interventions
Paclitaxel
4
fosbretabulin
3
Radiotherapy
3
selpercatinib
2
Filgrastim
2
Everolimus
2
Doxorubicin
2
Cisplatin
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
sargramostim
1
repotrectinib
1
pralsetinib
1
pentetreotide
1
pegfilgrastim
1
mercaptoundecahydrododecaborate
1
gallium Ga 68 dotatate
1
fostamatinib
1
entrectinib
1
combretastatin
1
alectinib
1
aldesleukin
1
Triiodothyronine
1
Thyrotropin Alfa
1
Thyrotropin
1
Thalidomide
1
Tamoxifen
1
Semaxinib
1
Rosiglitazone
1
Radiofrequency Ablation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
entrectinib
×
Endocrine
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA